Corticosteroids can cause fractures by reducing bone formation and the viability of osteoblasts and osteocytes. The heightened fracture risk is dose dependent and occurs within months of starting therapy. Daily doses of more than 2.5 mg prednisolone or equivalent are associated with a higher fracture risk. Randomised studies reveal adverse skeletal effects with daily doses as low as 5 mg. After treatment stops, the fracture risk rapidly falls towards baseline unless the patient was taking long-term therapy. Patients who start corticosteroid therapy should routinely receive calcium and vitamin D supplementation. Those with a higher risk of fracture should also be offered a bisphosphonate. Repeated efforts should be made to reduce the dose of corticosteroids or discontinue long-term therapy if possible.
Introduction
Fragility fractures are a serious complication of long-term treatment with corticosteroids. The high frequency and rapid onset of corticosteroid-related fractures necessitates prompt identification of at-risk patients.
A meta-analysis of more than 42 000 patients compared outcomes for patients who had taken oral corticosteroids with those who had not. The relative risk for osteoporotic fracture was 2.63 at the age of 50 and 1.71 at 85 years. For hip fracture the respective relative risks were 4.42 and 2.48. Overall, the reported fracture risk was similar in men and women, independent of prior fracture, and only partially explained by losses in bone mineral density. 1 In a retrospective study of a general practice database (244 235 people taking oral corticosteroids were compared with the same number of controls) the relative rate was 1.61 for hip fracture and 2.60 for vertebral fracture. The fracture risk increased with daily prednisolone doses greater than 2.5 mg/day and no truly 'safe dose' of corticosteroid was identified. Importantly, fracture rates decreased rapidly (within one year) after cessation of oral corticosteroid therapy, indicating reversibility of the risk. (calcitriol). In some patients, corticosteroids also reduce gonadal function, which may further contribute to bone fragility.
The role of steroid-induced myopathy on fractures is unknown.
The increase over time of both vertebral and non-vertebral fractures without an increase in forearm fractures suggests that the direct effects of corticosteroids on bone strength predominate over any effects on falls.
effects of dosage and timing
Short-term studies show that daily doses of prednisolone as low as 5 mg cause markers of bone formation (for example osteocalcin) to fall rapidly. Both the daily dose and treatment duration, and therefore cumulative dose, are considered responsible for the skeletal adverse effects. However, as to short-term treatment. 4 Hence, fracture risk reduction after withdrawal of corticosteroids is less certain after long-term therapy than after short-term therapy.
In contrast to premenopausal women, people aged over 
Risk assessment
Each patient's risk factors should be carefully appraised before prescribing corticosteroids ( 
Calcium and vitamin D

Antiresorptive drugs
Although the effects of corticosteroids on bone formation predominate, antiresorptive drugs appear to reduce fracture risk 
Anabolic drugs
Intermittent injections of parathyroid hormone have a bone anabolic effect. A randomised clinical trial showed that recombinant human parathyroid hormone injections could override corticosteroid-induced suppression of bone formation and increase bone mass. 10 However, the precise role and cost-effectiveness of recombinant parathyroid hormone in postmenopausal and corticosteroid-induced osteoporosis has not been defined.
Recommendations
Postmenopausal women taking oral corticosteroids have the highest risk of bone loss and vertebral fracture so prophylaxis should be considered. In men and premenopausal women, the decision to intervene is less clear and depends on factors such as the baseline bone mineral density and the anticipated duration and dose of corticosteroid therapy (Fig. 1) .
Oral bisphosphonates, such as alendronate and risedronate, In patients on long-term low-dose prednisolone (< 7.5 mg/day or equivalent), calcium and vitamin D 3 therapy may be sufficient to prevent continuing bone loss and reduce falls. However, patients who continue to lose bone or those at high risk of fracture (previous fragility fracture, bone density < -1.5) should also be offered oral bisphosphonates. Although most clinical trial data are limited to 1-2 years, it is rational to maintain fracture prophylaxis for as long as corticosteroids are taken at a daily dose of more than 5 mg prednisolone or equivalent.
Self-test questions
The following statements are either true or false (answers on page 55)
5. The effectiveness of bisphosphonates in preventing hip fracture in patients taking corticosteroids is unknown.
6. Calcium prevents the rapid loss of bone mineral density in patients starting corticosteroids.
New drugs
Some of the views expressed in the following notes on newly approved products should be regarded as tentative, as there may be limited published data and little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. As a result of fuller experience, initial comments may need to be modified. The Committee is prepared to do this. Before new drugs are prescribed, the Committee believes it is important that full information is obtained either from the manufacturer's approved product information, a drug information centre or some other appropriate source. Median time to progression was around 11 months with combination therapy compared to just under 5 months with dexamethasone alone. 4, 5 Monitoring of complete blood counts is recommended because neutropenia and thrombocytopenia are very common with lenalidomide (especially when used with dexamethasone) and patients often need their dose to be reduced or interrupted.
Growth factors may be needed for patients with neutropenia.
There is also an increased risk of deep vein thrombosis and pulmonary embolism in patients taking lenalidomide with
